President’s Report – 2025

We successfully held our annual gala on April 24, 2025, in New Jersey but it is becoming increasingly difficult to secure both donations and attendees in what many would agree is a challenging environment of macroeconomic and geopolitical uncertainty as well as changing demographics.  Despite this, the gala continues to be our largest fundraising event held during the year, and we are very appreciative of all those that support us. 

Our focus continues to be on sponsoring research and increasing awareness.  

During 2025, we approved and issued three grants.  The institutions receiving these grants were the University of Arizona, Stanford University and the University of Auckland.

Details of the work being performed and their latest updates can be found on our website at www.sdhbcoalition.org.

We believe that progress is being made, albeit slowly, given that this is complex, time-consuming and challenging work. We are very appreciative for the dedication and commitment made by all of these institutions and remain confident that this research will produce better treatment options for patients and healthcare providers in the future.

In addition to the institutions previously mentioned, we would be remiss if we did not acknowledge the past and ongoing work of the following institutions, namely Tufts Medical Center, Columbia University, University of Alabama at Birmingham, University of Florida, Broad Institute of MIT at Harvard, University of Melbourne and Linkoping University in Sweden.

In addition, we were one of a number of contributors that sponsored ISP2025, held on September 18-20, 2025, in Montreal, Canada, an international symposium where scientists and SME’s from around the world come together to discuss developments, new science, innovation and therapeutic options in the field of Pheochromocytoma’s and Paraganglioma’s respectively.

We have continued our work to increase awareness through our outreach efforts and social media presence.  We remain active on Facebook, Instagram and LinkedIn respectively and are updating our website as and when new information becomes available.

Our objectives for 2026 are consistent with previous years and are as follows:

1. Continue to sponsor research at credible institutions who have demonstrated their commitment and experience in the SDHB neuroendocrine tumor space.
2. Continue our efforts to increase awareness with the goal of recruiting new sponsors / contributors in this regard.
3. Expand our fundraising programs to include new target audiences and philanthropic contributors with the goal of maintaining or increasing our annual revenue stream.

In summary, I want to thank all who have supported our mission, made donations, volunteered their time without which we would not be where we are today. 

Your support is greatly appreciated.

Nick Rothwell
President
SDHB Coalition, Inc.